Healthcare Nov 29, 2021 06:24 PM (GMT+8) · EqualOcean
On November 29, Suzhou Aibo Biotechnology Co., Ltd. announced that it had completed the round C + financing of US $300 million. This round of financing is jointly led by Softbank vision fund and original shareholder Wuyuan capital, followed by chimera Abu Dhabi, Fuhai growth fund, Jinyi capital, Xinfeng Tianyu, IMO ventures, future asset group, etc. This round of financing will support Aibo biology to accelerate the clinical development and internationalization of Xinguan mRNA vaccine products, further improve the R & D competitiveness of mRNA platform, rapidly expand clinical pipeline, expand production capacity and comprehensively speed up the commercial layout in combination with cross-border technologies such as artificial intelligence.